Key result
Emerging technologies such as non-coding RNAs, epigenetic factors, and extracellular vesicles offer new insights into the pathophysiology and potential diagnosis of Cardiorenal Syndrome Type 3.
Why the study?
A large amount of information generated by omics technologies needs to be linked to better understand intermediaries in the kidney-heart axis, particularly in cardiorenal syndrome type 3.
This review emphasizes the potential of 'Omics' technologies, specifically non-coding RNAs and epigenetic factors, as future biomarkers and therapeutic targets for understanding and managing cardiorenal syndrome type 3.
Answers are grounded in this paper and cite their sources.
CRS classification advances cardiorenal understanding; leaves open optimal integration of emerging technologies into care.
The pathologies of the kidney and heart have instigated a large number of researchers around the world to try to better understand what the exact connectors responsible for the emergence and establishment of these diseases are. The classification of these pathologies into different types of cardiorenal syndromes (CRSs) over the last 15 years has greatly contributed to understanding pathophysiological and diagnostic aspects, as well as treatment strategies. However, with the advent of new technologies classified as "Omics", a new range of knowledge and new possibilities have opened up in order to effectively understand the intermediaries between the kidney-heart axis. The universe of micro-RNAs (miRNAs), epigenetic factors, and components present in extracellular vesicles (EVs) have been protagonists in studying different types of CRSs. Thus, the new challenge that is imposed is to select and link the large amount of information generated from the use of large-scale analysis techniques. The present review seeks to present some of the future perspectives related to understanding CRSs, with an emphasis on CRS type 3.
No takes yet. Share an insight, caveat, or question.
Neres-Santos et al. (2023) conducted a review in Cardiorenal Syndrome Type 3. Cardiorenal Syndrome Type 3 pathophysiology and biomarkers was evaluated. Emerging technologies such as non-coding RNAs, epigenetic factors, and extracellular vesicles offer new insights into the pathophysiology and potential diagnosis of Cardiorenal Syndrome Type 3.
Synapse has enriched 10 related papers. Consider them for comparative context: